The fact that nilotinib eliminated FBS-induced p38 MAPK phosphorylation (Fig. 4) and that inhibition of this kinase reduces MDR in some human cancer cells by modulating P-gp expression [24], [25], suggested to analyze the effect of nilotinib and DXR on p38 MAPK phosphorylation. Here, PGP is linked to cancer.